The agenda outlines priority questions trials can address, aiming to generate public health benefits for at-risk children.

Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate ...

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials ...

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with ...

Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Philogen SpA ( ($IT:PHIL) ) just unveiled an announcement. Philogen S.p.A. has reported a positive net financial position of 369,164 thousand ...

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...

The ExacTcell™ platform utilizes advanced immunological screening as well as laboratory testing to identify key targets recognized by the immune system across different HLA types. With this expanded ...

Infections caused by a highly drug-resistant and dangerous bacteria known as NDM-producing carpabenem-resistant Enterobacterales, or NDM-CRE, have surged by more than 460% in the U.S. between 2019 and ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...